Abstracts Archive - Page 423 of 2605 - ACR Meeting Abstracts

Abstract Number: 1752 • ACR Convergence 2023
Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint
Chunyan Xiang¹, Soomin Hong¹, Bingjiao Zhao², Hui Pi³, Fang Du⁴, Xingyu Lu⁵, Yuanjia Tang¹, Nan Shen⁶, Chunxi Yang⁷ and Runci Wang⁸, ¹Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ²Department of Orthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China, ³Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China, ⁴Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ⁵Department of Endocrinology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁶Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁷Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ⁸Renji hospital, Shanghai Jiaotong University, Pudong Xinqu, China
Background/Purpose: Peripheral neuroimmune crosstalk plays a crucial role in the inflammatory process and bone metabolism in joint. Serotonin receptor HTR2A was reported to be expressed…
Abstract Number: 1756 • ACR Convergence 2023
Circulating CD4+CD25+CD127-FoxP3+CD39+ T Cells Predict the Response to Methotrexate Across Basal Disease Activity Strata in Early Rheumatoid Arthritis
Maria-Eugenia Miranda-Carus¹, Beatriz Nieto-Carvalhal¹, Alejandro Villalba², Laura Nuño¹, Marta Benito-Miguel³, Marta Novella-Navarro⁴, Irene Monjo⁵, Diana Peiteado¹, Sara García-Carazo¹ and Alejandro Balsa⁴, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital, Madrid, Spain, ³Universidad Nebrija, Physiology, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵University Hospital La Paz, Madrid, Spain
Background/Purpose: A subset of human FoxP3+ regulatory T (Treg) cells expresses CD39 (Treg39+) and hydrolyses proinflammatory adenine nucleotides released at inflammatory foci, rendering the antiinflamatory…
Abstract Number: 1579 • ACR Convergence 2023
Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Natalie McCormick¹, Chio Yokose¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2) have benefits on kidney and cardiovascular (CV) outcomes that are largely independent of glycemic control. These benefits have been demonstrated…
Abstract Number: 1726 • ACR Convergence 2023
Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis
Melissa Lim¹, Shaghayegh Foroozan², Zoya Qaiyum³, Michael Tang¹, Enoch Yau⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University Health Network/University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis primarily affecting the axial skeleton and commonly coexists with gut and skin inflammation. Currently, patients with…
Abstract Number: 1913 • ACR Convergence 2023
Neurosarcoidosis Disease Epidemiology. University Hospital in Northern Spain 1999-2019
Ana Serrano-Combarro¹, Alba Herrero-Morant², Lara Sanchez-Bilbao³, Inigo Gonzalez-Mazon³, David Martinez-Lopez⁴, Jose Luis Martin-Varillas⁵, Raul Fernandez-Ramon⁶ and Ricardo Blanco⁷, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Hospital de Sierrallana, Santander, Spain, ⁵Hospital de Laredo, Laredo, Spain, ⁶Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Neurosarcoidosis (NS) is a serious and relative uncommon complication of sarcoidosis. Data on incidence is scarce and varies worldwide. Our objective is toestimate NS…
Abstract Number: 1917 • ACR Convergence 2023
Reducing Inadvertent Antifilarial Antibody Testing at an Academic Medical Center: A Quality Improvement Project
Khiem Vu, Justin Choi and Jon Golenbiewski, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC
Background/Purpose: IgG4-Related Disease (IgG4-RD) is a fibroinflammatory autoimmune disease that can present with glandular swelling, chronic pancreatitis, sclerosing cholangitis, and retroperitoneal fibrosis, amongst others. Along…
Abstract Number: 1378 • ACR Convergence 2023
The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study
Gaetano La Rocca¹, Francesco Ferro², Elena Elefante³, Silvia Fonzetti⁴, Giovanni Fulvio⁵, Inmaculada Conception Navarro Garcia³, Chiara Romei⁶, Marta Mosca³ and Chiara Baldini⁵, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴AOUP, Pisa, Italy, ⁵University of Pisa, Pisa, Italy, ⁶Department of Diagnostic Imaging, Diagnostic Radiology 2, Pisa University Hospital, Pisa, Italy
Background/Purpose: In clinical trials investigating new drugs for the management of Interstitial Lung Disease (ILD) patient reported outcomes (PRO) are increasingly employed as outcome measures…
Abstract Number: 1760 • ACR Convergence 2023
Methotrexate Augments the Release of Granulocyte-macrophage Colony-stimulating Factor from Activated Rheumatoid Arthritis Fibroblast-like Synoviocytes – Possible Consequences for Persistence of Joint Inflammation
Beatrice Bergström¹, Tilia Selldén¹, Miriam Bollmann², Mattias N.D Svensson¹ and Anna-Karin Hultgård Ekwall³, ¹University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³University of Gothenburg, Kullavik, Sweden
Background/Purpose: Activated fibroblast-like synoviocytes (FLS) are important mediators of synovitis and structural damage in rheumatoid arthritis (RA)[1]. Granulocyte-macrophage colony-stimulating factor (GM-CSF, encoded by the CSF2…
Abstract Number: 1690 • ACR Convergence 2023
Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
Mikkel Østergaard¹, Walter P. Maksymowych², Mikael Boesen³, Robert Lambert⁴, Guillermo Valenzuela⁵, Michael Bubb⁶, Olga Kubassova⁷, Jyotsna Reddy⁸, Stephen Colgan⁹, Yuri Klyachkin¹⁰, Cynthia Deignan¹¹, Lihua Tang⁸, Maria Paris⁸ and Philip J. Mease¹², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ²University of Alberta, Edmonton, AB, Canada, ³Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ⁴Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶University of Florida, Gainesville, FL, ⁷Image Analysis Group, Philadelphia, PA, ⁸Amgen, Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Halton Hills, ON, Canada, ¹⁰Amgen, Inc., Lexington, KY, ¹¹Amgen, Inc., Agoura Hills, CA, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: PsA is characterized by inflammatory arthritis, enthesitis, dactylitis, and spondylitis. Apremilast (APR) is an oral immunomodulating phosphodiesterase-4 inhibitor approved for the treatment of PsA.…
Abstract Number: 1588 • ACR Convergence 2023
Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing
Xiaoya Pei¹, Jia Shi², Yangzhong Zhou², Xiao Zhang², Xiaoman Wang¹, Mingwei Tang², Shuang Zhou², chanyuan wu², Jinmin Peng³, Mengtao Li⁴, xiaofeng Zeng², Jun Liu⁵, Houzao Chen¹ and Qian Wang², ¹State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China
Background/Purpose: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM) is a rare inflammatory autoimmune disease with impressively life-threatening rapid progressive interstitial lung disease (RP-ILD). The mechanism…
Abstract Number: 1915 • ACR Convergence 2023
Scleritis and Development of Autoimmune Disease: A Case Series
Tessalyn Morrison¹, Moriah Gottman², Marcia Friedman³ and Daniela Ghetie⁴, ¹University of Vermont, Burlington, VT, ²Oregon Health & Science University, Milwaukie, OR, ³Alpine Immune Sciences, Inc., Beaverton, OR, ⁴Oregon Health & Science University, Portland, OR
Background/Purpose: Scleritis involves inflammation of the sclera caused by trauma, infections, or autoimmune conditions. The purpose of our study was to understand the relationship between…
Abstract Number: 1916 • ACR Convergence 2023
Clinical Features of the Patients with NLRP1 Gene Variants and a Systemic Autoinflammatory Phenotype
Shirkhan Amikishiyev¹, Tuğba Kalaycı², Rabia Deniz³, Yasemin Yalçınkaya⁴, Bahar Artim-Esen¹, Murat Inanc¹, Ayla Sahin², Sema Sırma Ekmekci⁵, Neslihan Abacı⁵, Sukru Ozturk², Sukru Palanduz² and Ahmet Gul¹, ¹Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ²Department of Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³Division of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey
Background/Purpose: Although NLRP1 was the first identified member of the NOD-like receptors family, its role as a sensor of pathogen- or damage-associated signals and its…
Abstract Number: 1912 • ACR Convergence 2023
Impact of Pharmacist-Led Specialty Medication Management Service on Time-to-Dispense for Specialty Rheumatologic Medications in a University Health System
Khashayar Ahmadmehrabi¹, Navin Ravishankar², Diana Mekhiel³ and Zineb Aouhab³, ¹Loyola University Medical Center, Oak Park, IL, ²Indiana University Health, Indianapolis, IN, ³Loyola University Medical Center, Maywood, IL
Background/Purpose: Given the progressive joint damage and physical disability associated with uncontrolled Rheumatoid arthritis (RA), a treat-to target-strategy through the early utilization of disease-modifying antirheumatic…
Abstract Number: 1914 • ACR Convergence 2023
Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes
Cristina Corrales Selaya¹, David Martínez-Lopez², Diana Prieto-Peña¹, Fabricio Benavides¹, Jose Luis Martin-Varillas³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterised mainly by the presence of inflammation and muscle weakness. The main subtypes of…
Abstract Number: 1386 • ACR Convergence 2023
Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
Huseyin Berk Degirmenci¹, Christine E. Peloquin², Sara Lodi², Pedro Machado³, S. Reza Jafarzadeh⁴, Tuhina Neogi⁵, Lianne Gensler⁶, Maureen Dubreuil⁷ and Jean Liew², ¹St. Elizabeth's Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁷Department of Rheumatology, Boston University School of Medicine, Milton, MA
Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].